Improved Working Memory but No Effect on Striatal Vesicular Monoamine Transporter Type 2 after Omega-3 Polyunsaturated Fatty Acid Supplementation

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Narendran, Rajesh ^a   Frankle, William G ^a   Mason, Neale S ^a   Muldoon, Matthew F ^a   Moghaddam, Bita ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DIHYDROTETRABENAZINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; BINDING KINETICS; COGNITION; CORPUS STRIATUM; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID COMPOSITION; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; TASK PERFORMANCE; VOLUNTEER; WORKING MEMORY;

DIETARY SUPPLEMENTS; DOPAMINE; ERYTHROCYTE MEMBRANE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

RODENTIA;

EID: 84867050382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046832     Document Type: Article

References (44)

1. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, et al. (2006) Omega-3 fatty acids and mood disorders. The American journal of psychiatry 163: 969-978.
2. Muldoon MF, Ryan CM, Sheu L, Yao JK, Conklin SM, et al. (2010) Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. The Journal of nutrition 140: 848-853.
3. Turnbull T, Cullen-Drill M, Smaldone A, (2008) Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review. Arch Psychiatr Nurs 22: 305-311.
4. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, et al. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67: 146-154.
5. Richardson AJ, (2006) Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 18: 155-172.
6. Sarris J, Mischoulon D, Schweitzer I, (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73: 81-86.
7. Sublette ME, Ellis SP, Geant AL, Mann JJ, (2011) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 72: 1577-1584.
8. Fusar-Poli P, Berger G, (2012) Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 32: 179-185.
9. Ortega RM, Rodriguez-Rodriguez E, Lopez-Sobaler AM, (2012) Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders. The British journal of nutrition 107Suppl 2: S261-270.
10. Chalon S, (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 75: 259-269.
11. Zimmer L, Durand G, Guilloteau D, Chalon S, (1999) n-3 polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids 34Suppl: S251.
12. Zimmer L, Vancassel S, Cantagrel S, Breton P, Delamanche S, et al. (2002) The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr 75: 662-667.
13. Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, et al. (2000) Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res 41: 32-40.
14. Kodas E, Vancassel S, Lejeune B, Guilloteau D, Chalon S, (2002) Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J Lipid Res 43: 1209-1219.
15. Delion S, Chalon S, Herault J, Guilloteau D, Besnard JC, et al. (1994) Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr 124: 2466-2476.
16. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G, (1996) alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 66: 1582-1591.
17. Zimmer L, Delpal S, Guilloteau D, Aioun J, Durand G, et al. (2000) Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 284: 25-28.
18. Reddy RD, Keshavan MS, Yao JK, (2004) Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophrenia bulletin 30: 901-911.
19. Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, et al. (2008) Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. Journal of the American College of Cardiology 52: 417-424.
20. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, et al. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22: 3708-3719.
21. Goldman-Rakic PS, (1994) Working memory dysfunction in schizophrenia. Journal of Neuropsychiatry & Clinical Neurosciences 6: 348-357.
22. Arnsten AF, Goldman-Rakic PS, (1998) Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry 55: 362-368.
23. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS, (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116: 143-151.
24. Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K, (1995) Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 278: 249-252.
25. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, et al. (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26: 1198-1212.
26. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, et al. (1997) Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[C-11]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 17: 919-931.
27. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, et al. (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21: 1034-1057.
28. Chan GL, Holden JE, Stoessl AJ, Samii A, Doudet DJ, et al. (1999) Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40: 283-289.
29. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB, (1994) Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 83: 1014-1019.
30. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, et al. (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
31. Narendran R, Mason NS, Laymon C, Lopresti B, Velasquez N, et al. (2010) A comparative evaluation of the dopamine D2/3 agonist radiotracer [11C]NPA and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. Journal of Pharmacology and Experimental Therapeutics 63: 574-584.
32. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
33. Stough C, Downey L, Silber B, Lloyd J, Kure C, et al. (2012) The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiology of aging 33: 824 e821-823.
34. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, et al. (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Archives of neurology 63: 1402-1408.
35. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International journal of geriatric psychiatry 23: 161-169.
36. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, et al. (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Progress in neuro-psychopharmacology & biological psychiatry 32: 1538-1544.
37. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, et al. (2008) Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 71: 430-438.
38. Arnsten AF, (2011) Catecholamine influences on dorsolateral prefrontal cortical networks. Biological psychiatry 69: e89-99.
39. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, et al. (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14.
40. Moghaddam B, Berridge CW, Goldman-Rakic PS, Bunney BS, Roth RH, (1993) In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13: 215-222.
41. Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, et al. (2012) In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. The American journal of psychiatry 169: 55-63.
42. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, et al. (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
43. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, et al. (2007) Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. The American journal of psychiatry 164: 622-629.
44. Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, et al. (2011) Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. The American journal of psychiatry 168: 634-641.